

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

January 12, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled “**U.S. FDA Classifies Biocon Biologics Site in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI).**”

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh
Nand

Digitally signed by
Akhilesh Nand
Date: 2025.01.12
11:59:02 +05'30'

Akhilesh Nand**Company Secretary**

Membership No. ACS 13669

Address: Biocon House, Semicon Park

Tower 3, Electronic City Phase 2, Hosur Road

Bengaluru, Karnataka

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

U.S. FDA Classifies Biocon Biologics Site in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI)

Bengaluru, Karnataka, India, January 12, 2025

“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI).

“This relates to the cGMP inspection conducted by the agency between September 15 – 27, 2024. The inspection scope had included several biologics manufacturing units comprising one (1) Drug Substance and one (1) Drug Product manufacturing units, one (1) Medical Device Assembly unit, one (1) Analytical Quality Control Laboratory, two (2) Microbiological Control Laboratories and two (2) Warehouses.

“Biocon Biologics remains committed to global standards of Quality and Compliance.”

– Company Spokesperson

For more information: seema.ahuja@biocon.com